



## PRESS RELEASE

*The information was submitted for publication on 30 November 2016 at 08.00 CET.*

## Increased number of shares and votes in Probi

**As previously announced, Probi AB (publ) ("Probi") has carried out a rights issue of no more than 2,278,825 shares. The 33,835 shares subscribed for without subscription rights have been registered with the Swedish Companies Registration Office during November 2016, and the number of shares and votes in the company have therefore increased as set forth below.**

As of 30 November 2016, the total number of shares in Probi amounts to 11,644,125, corresponding to 11,644,125 votes.

*This information is information that Probi AB is obliged to make public pursuant to the Financial Instruments Trading Act.*

### FOR FURTHER INFORMATION, CONTACT:

Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23, e-mail: [peter.nahlstedt@probi.se](mailto:peter.nahlstedt@probi.se)  
Niklas Brandt, CFO, Probi, tel +46 46 286 89 26, e-mail: [niklas.brandt@probi.se](mailto:niklas.brandt@probi.se)

### ABOUT PROBI

*Probi AB is a Swedish publicly traded bioengineering company that develops effective and well-documented probiotics. Through its world-leading research, Probi has created a strong product portfolio in the gastrointestinal health and immune system niches. Probi's products are available to consumers in more than 30 countries worldwide. Probi's customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. In 2015 Probi had sales of MSEK 216. The Probi share is listed on Nasdaq Stockholm, Small Cap. Probi has about 4,400 shareholders. Read more at [www.probi.se](http://www.probi.se).*